Boron neutron capture therapy outcomes for advanced or recurrent head and neck cancer.

Suzuki, Minoru
Kato, Ituro
Aihara, Teruhito
Hiratsuka, Junichi
Yoshimura, Kenichi
Niimi, Miyuki
Kimura, Yoshihiro
Ariyoshi, Yasunori
Haginomori, Shin-Ichi
Sakurai, Yoshinori
Kinashi, Yuko
Masunaga, Shin-Ichiro
Fukushima, Masanori
Ono, Koji
Maruhashi, Akira

Open PDF

Open link

Publication date

January 2014

DOI

10.1093/jrr/rrt098

Publisher

Oxford University Press (OUP)

Journal

Journal of Radiation Research

Abstract

We retrospectively review outcomes of applying boron neutron capture therapy (BNCT) to unresectable advanced or recurrent head and neck cancers. Patients who were treated with BNCT for either local recurrent or newly diagnosed unresectable head or neck cancers between December 2001 and September 2007 were included. Clinicopathological characteristics and clinical outcomes were retrieved from hospital records. Either a combination of borocaptate sodium and boronophenylalanine (BPA) or BPA alone were used as boron compounds. In all the treatment cases, the dose constraint was set to deliver a dose <10-12 Gy-eq to the skin or oral mucosa. There was a patient cohort of 62, with a median follow-up of 18.7 months (range, 0.7-40.8). A total of 87 ...